Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Renal Insufficiency 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Melphalan 5Filgrastim 4birtamimab 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pomalidomide 2Calcium Dobesilate 2Bortezomib 2venetoclax 1pegfilgrastim 1nelarabine 1melflufen 1daratumumab 1Tetradecanoylphorbol Acetate 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Moxifloxacin 1Morphine 1Methadone 1Fluorescent Antibody Technique 1Fentanyl 1Diuretics 1Ciprofloxacin 1Blood Component Removal 1Amoxicillin-Potassium Clavulanate Combination 1Amifostine 14'-deoxy-4'-iododoxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immunoglobulin Light-chain Amyloidosis × melflufen × Clear all
NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡